首页 > 最新文献

Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko最新文献

英文 中文
[Radiosurgery for cerebral cavernous malformations: a systematic review]. [放射外科治疗脑海绵畸形:系统性综述]。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.17116/neiro202488041107
D E Semenov, O B Belousova, V V Kostyuchenko, A V Golanov

Background: Stereotactic radiosurgery (SRS) for cerebral cavernous malformations has been used for more than 30 years. However, indications for this method and outcomes are still discussable.

Objective: To analyze available literature data on SRS for cerebral cavernous malformations with assessment of indications for treatment, radiation parameters, radiological and clinical complications and outcomes.

Results: The final analysis included 20 reports describing post-SRS outcomes in 1834 patients with cerebral cavernous malformations. The main radiation parameter was mean radiation dose to the edge of cavernous malformation (prescribed dose, 13.25±2.16 Gy). In natural course of malformation, mean incidence of hemorrhages from cavernous malformation when counted after the second hemorrhage was 25.9±14.6%, after the patient's birth - 2.59±0.44%. Mean follow-up period after SRS was 66.7±24.1 months. Incidence of hemorrhages from cavernous malformation after SRS for the first 2 years of follow-up was assessed in 14 studies (4.67±3.51%). Incidence of hemorrhages ≥2 years after SRS was analyzed in 12 studies (1.55±0.8%).

Conclusion: Despite significant global experience in SRS for cerebral cavernous malformations and many studies devoted to this problem, clear patient selection criteria have not yet been formulated. Modern selection principles have insufficient evidence base.

背景:立体定向放射外科手术(SRS)治疗脑海绵畸形已有 30 多年的历史。然而,这种方法的适应症和结果仍有待讨论:目的:分析现有SRS治疗脑海绵畸形的文献数据,评估治疗适应症、放射参数、放射学和临床并发症及疗效:最终分析包括20篇报告,描述了1834名脑海绵畸形患者的SRS术后效果。主要的放射参数是海绵畸形边缘的平均放射剂量(规定剂量,13.25±2.16 Gy)。在畸形的自然病程中,如果在第二次出血后计算,海绵畸形出血的平均发生率为(25.9±14.6)%,在患者出生后--为(2.59±0.44)%。SRS 后的平均随访时间为 66.7±24.1 个月。14项研究评估了SRS术后头2年随访中海绵畸形出血的发生率(4.67±3.51%)。12项研究分析了SRS术后≥2年的出血发生率(1.55±0.8%):结论:尽管全球在脑海绵畸形的SRS方面积累了丰富的经验,也有许多专门针对这一问题的研究,但尚未制定明确的患者选择标准。现代选择原则缺乏足够的证据基础。
{"title":"[Radiosurgery for cerebral cavernous malformations: a systematic review].","authors":"D E Semenov, O B Belousova, V V Kostyuchenko, A V Golanov","doi":"10.17116/neiro202488041107","DOIUrl":"10.17116/neiro202488041107","url":null,"abstract":"<p><strong>Background: </strong>Stereotactic radiosurgery (SRS) for cerebral cavernous malformations has been used for more than 30 years. However, indications for this method and outcomes are still discussable.</p><p><strong>Objective: </strong>To analyze available literature data on SRS for cerebral cavernous malformations with assessment of indications for treatment, radiation parameters, radiological and clinical complications and outcomes.</p><p><strong>Results: </strong>The final analysis included 20 reports describing post-SRS outcomes in 1834 patients with cerebral cavernous malformations. The main radiation parameter was mean radiation dose to the edge of cavernous malformation (prescribed dose, 13.25±2.16 Gy). In natural course of malformation, mean incidence of hemorrhages from cavernous malformation when counted after the second hemorrhage was 25.9±14.6%, after the patient's birth - 2.59±0.44%. Mean follow-up period after SRS was 66.7±24.1 months. Incidence of hemorrhages from cavernous malformation after SRS for the first 2 years of follow-up was assessed in 14 studies (4.67±3.51%). Incidence of hemorrhages ≥2 years after SRS was analyzed in 12 studies (1.55±0.8%).</p><p><strong>Conclusion: </strong>Despite significant global experience in SRS for cerebral cavernous malformations and many studies devoted to this problem, clear patient selection criteria have not yet been formulated. Modern selection principles have insufficient evidence base.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Minimally invasive removal of dumbbell shaped schwannomas with transforaminal lumbar fusion: a retrospective study with a minimum 3-year follow-up]. [经椎间孔腰椎融合术微创切除哑铃形神经管瘤:至少 3 年随访的回顾性研究]。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.17116/neiro20248802147
V A Byvaltsev, A A Kalinin

Currently, there are no standards in surgical treatment of dumbbell-shaped tumors of lumbo-foraminal region.

Objective: To evaluate the effectiveness and long-term results of minimally invasive resection of dumbbell-shaped lumbar schwannomas Eden type 2 and 3 combined with transforaminal lumbar interbody fusion and transpedicular stabilization.

Material and methods: A retrospective study included 13 patients (8 men and 5 women) with lumbar dumbbell tumors Eden type 2 and 3 who underwent minimally invasive facetectomy through posterolateral anatomical corridor, microsurgical tumor resection and MI TLIF. We analyzed intraoperative parameters, neurological functions (ASIA scale), clinical characteristics (ODI, SF-36), and complications. Resection quality and area of the multifidus muscle were assessed according to MRI data. All patients were followed-up throughout at least 3-year.

Results: Surgery time was 147 min, blood loss - 118 ml, hospital-stay - 7 days. Clinical parameters significantly improved in the follow-up period: ODI score decreased from 72 to 12 (p=0.004), SF-36 PCS increased from 26.24 to 48.51 (p=0.006) and MCS score increased from 29.13 to 53.68 (p=0.002). According to MRI data, no tumor recurrences and severe muscle atrophy (>30%) were observed after 3 years in all cases. Superficial wound infection occurred in 1 (7.7%) case. There were normal neurological functions (ASIA type E) in all patients.

Conclusion: Minimally invasive facetectomy through posterolateral approach with MI TLIF technology can be used for safe and effective resection of dumbbell-shaped schwannomas Eden type 2 and 3.

目前,尚无针对腰椎椎间孔哑铃状肿瘤的手术治疗标准:评估伊登 2 型和 3 型哑铃状腰椎裂孔瘤微创切除术联合经椎间孔腰椎椎体间融合术和跨关节稳定术的有效性和长期效果:这是一项回顾性研究,纳入了13例(8男5女)Eden 2型和3型腰椎哑铃状肿瘤患者,他们接受了经后外侧解剖走廊的微创面神经切除术、显微外科肿瘤切除术和MI TLIF。我们对术中参数、神经功能(ASIA量表)、临床特征(ODI、SF-36)和并发症进行了分析。根据核磁共振成像数据评估切除质量和多裂肌面积。所有患者均接受了至少3年的随访:手术时间为147分钟,失血量为118毫升,住院时间为7天。随访期间,临床指标明显改善:ODI评分从72分降至12分(P=0.004),SF-36 PCS从26.24分升至48.51分(P=0.006),MCS评分从29.13分升至53.68分(P=0.002)。根据核磁共振成像数据,所有病例在 3 年后均未观察到肿瘤复发和严重肌肉萎缩(>30%)。1例(7.7%)发生了表皮伤口感染。所有患者的神经功能均正常(ASIA E型):结论:采用MI TLIF技术的后外侧微创面神经切除术可安全有效地切除伊登2型和3型哑铃状分裂瘤。
{"title":"[Minimally invasive removal of dumbbell shaped schwannomas with transforaminal lumbar fusion: a retrospective study with a minimum 3-year follow-up].","authors":"V A Byvaltsev, A A Kalinin","doi":"10.17116/neiro20248802147","DOIUrl":"10.17116/neiro20248802147","url":null,"abstract":"<p><p>Currently, there are no standards in surgical treatment of dumbbell-shaped tumors of lumbo-foraminal region.</p><p><strong>Objective: </strong>To evaluate the effectiveness and long-term results of minimally invasive resection of dumbbell-shaped lumbar schwannomas Eden type 2 and 3 combined with transforaminal lumbar interbody fusion and transpedicular stabilization.</p><p><strong>Material and methods: </strong>A retrospective study included 13 patients (8 men and 5 women) with lumbar dumbbell tumors Eden type 2 and 3 who underwent minimally invasive facetectomy through posterolateral anatomical corridor, microsurgical tumor resection and MI TLIF. We analyzed intraoperative parameters, neurological functions (ASIA scale), clinical characteristics (ODI, SF-36), and complications. Resection quality and area of the multifidus muscle were assessed according to MRI data. All patients were followed-up throughout at least 3-year.</p><p><strong>Results: </strong>Surgery time was 147 min, blood loss - 118 ml, hospital-stay - 7 days. Clinical parameters significantly improved in the follow-up period: ODI score decreased from 72 to 12 (<i>p</i>=0.004), SF-36 PCS increased from 26.24 to 48.51 (<i>p</i>=0.006) and MCS score increased from 29.13 to 53.68 (<i>p</i>=0.002). According to MRI data, no tumor recurrences and severe muscle atrophy (>30%) were observed after 3 years in all cases. Superficial wound infection occurred in 1 (7.7%) case. There were normal neurological functions (ASIA type E) in all patients.</p><p><strong>Conclusion: </strong>Minimally invasive facetectomy through posterolateral approach with MI TLIF technology can be used for safe and effective resection of dumbbell-shaped schwannomas Eden type 2 and 3.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140319442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Electrical dorsal root ganglion stimulation (DRGS) for the treatment of refractory postherpetic neuralgia]. [背根神经节电刺激(DRGS)用于治疗难治性带状疱疹后神经痛]。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.17116/neiro20248801121
E D Isagulyan, D E Semenov, A A Polushkin, S V Asriants, E V Sergeenko, K S Aslakhanova, A A Tomsky

Postherpetic neuralgia (PHN) is a rare complication of herpes zoster characterized by prolonged and excruciating pain. Traditional treatments for PHN, such as analgesics, anticonvulsants and antidepressants, do not always bring the desired result. One promising alternative that is attracting the attention of the scientific community is dorsal root ganglion stimulation (DRGS). This method focuses on targeted and precise targeting of the source of pain, providing a new level of effectiveness in the treatment of PHN.

Objective: A retrospective analysis of the technique and results of implantation of a permanent device for stimulating the spinal ganglia in patients with refractory PHN at the Burdenko Neurosurgical Center.

Material and methods: The study was conducted in 7 patients (5 men, 2 women) with refractory PHN in the period from 2018 to 2020. The age of the patients ranged from 57 to 84 years (average age 74±8.4). All patients were implanted with Boston systems (Precision or Spectra versions). Stimulation parameters: pulse width - 120-210 μs, frequency - 30-130 Hz, amplitude at the lower limit of the appearance of paresthesia with the possibility of increasing with increased pain up to 5 mA. The position of the electrode depended on the location of the pain. All systems were implanted under X-ray guidance.

Results: The duration of follow-up observation was more than 2.5 years. The average pain intensity one year after treatment was 3.42±2.45 points on the visual analogue scale (VAS) (a 62.3% decrease in intensity compared to baseline). In 3 (42.8%) patients, the result was characterized by us as «excellent» (intensity according to VAS decreased by 75% or more), in 1 (14.2%) - as «good» (intensity according to VAS decreased by 50-74%), in 1 (14.2%) - as «moderate» (VAS intensity decreased by 25-49% and in 2 (28.5%) as «unsatisfactory» (VAS intensity decreased by less than 25%, or postoperative complications occurred).

Conclusion: Given the complicated nature of PHN, the use of dorsal ganglion stimulation appears to be a promising and innovative treatment approach. Further research is needed to introduce this technique into clinical practice for the treatment of patients suffering from PHN.

带状疱疹后遗神经痛(PHN)是带状疱疹的一种罕见并发症,以长时间剧烈疼痛为特征。传统的 PHN 治疗方法,如止痛药、抗惊厥药和抗抑郁药,并不总能达到预期效果。背根神经节刺激疗法(DRGS)是一种前景广阔的替代疗法,正吸引着科学界的关注。这种方法侧重于有针对性地精确定位疼痛源,为 PHN 的治疗提供了一种新的有效方法:对布尔登科神经外科中心为难治性 PHN 患者植入刺激脊神经节永久装置的技术和结果进行回顾性分析:该研究在2018年至2020年期间对7名难治性PHN患者(5男2女)进行了研究。患者年龄从57岁到84岁不等(平均年龄为74±8.4岁)。所有患者均植入了波士顿系统(Precision 或 Spectra 版本)。刺激参数:脉宽 - 120-210 μs,频率 - 30-130 Hz,振幅在出现麻痹的下限,随着疼痛加剧可增加至 5 mA。电极的位置取决于疼痛的部位。所有系统均在 X 光引导下植入:随访观察时间超过 2.5 年。治疗一年后的平均疼痛强度为视觉模拟量表(VAS)上的 3.42±2.45(与基线相比,疼痛强度降低了 62.3%)。3例(42.8%)患者的治疗效果被我们评为 "极佳"(根据视觉模拟量表,疼痛强度下降了75%或更多),1例(14.2%)患者的治疗效果被我们评为 "良好"(根据视觉模拟量表,疼痛强度下降了50%-74%),1例(14.2%)患者的治疗效果被我们评为 "中等"(根据视觉模拟量表,疼痛强度下降了25%-49%),2例(28.5%)患者的治疗效果被我们评为 "不满意"(根据视觉模拟量表,疼痛强度下降了不到25%,或出现了术后并发症):鉴于 PHN 的复杂性,使用背神经节刺激似乎是一种很有前景的创新治疗方法。要将这一技术引入临床实践,用于治疗 PHN 患者,还需要进一步的研究。
{"title":"[Electrical dorsal root ganglion stimulation (DRGS) for the treatment of refractory postherpetic neuralgia].","authors":"E D Isagulyan, D E Semenov, A A Polushkin, S V Asriants, E V Sergeenko, K S Aslakhanova, A A Tomsky","doi":"10.17116/neiro20248801121","DOIUrl":"10.17116/neiro20248801121","url":null,"abstract":"<p><p>Postherpetic neuralgia (PHN) is a rare complication of herpes zoster characterized by prolonged and excruciating pain. Traditional treatments for PHN, such as analgesics, anticonvulsants and antidepressants, do not always bring the desired result. One promising alternative that is attracting the attention of the scientific community is dorsal root ganglion stimulation (DRGS). This method focuses on targeted and precise targeting of the source of pain, providing a new level of effectiveness in the treatment of PHN.</p><p><strong>Objective: </strong>A retrospective analysis of the technique and results of implantation of a permanent device for stimulating the spinal ganglia in patients with refractory PHN at the Burdenko Neurosurgical Center.</p><p><strong>Material and methods: </strong>The study was conducted in 7 patients (5 men, 2 women) with refractory PHN in the period from 2018 to 2020. The age of the patients ranged from 57 to 84 years (average age 74±8.4). All patients were implanted with Boston systems (Precision or Spectra versions). Stimulation parameters: pulse width - 120-210 μs, frequency - 30-130 Hz, amplitude at the lower limit of the appearance of paresthesia with the possibility of increasing with increased pain up to 5 mA. The position of the electrode depended on the location of the pain. All systems were implanted under X-ray guidance.</p><p><strong>Results: </strong>The duration of follow-up observation was more than 2.5 years. The average pain intensity one year after treatment was 3.42±2.45 points on the visual analogue scale (VAS) (a 62.3% decrease in intensity compared to baseline). In 3 (42.8%) patients, the result was characterized by us as «excellent» (intensity according to VAS decreased by 75% or more), in 1 (14.2%) - as «good» (intensity according to VAS decreased by 50-74%), in 1 (14.2%) - as «moderate» (VAS intensity decreased by 25-49% and in 2 (28.5%) as «unsatisfactory» (VAS intensity decreased by less than 25%, or postoperative complications occurred).</p><p><strong>Conclusion: </strong>Given the complicated nature of PHN, the use of dorsal ganglion stimulation appears to be a promising and innovative treatment approach. Further research is needed to introduce this technique into clinical practice for the treatment of patients suffering from PHN.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708068","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Hypothalamic hamartoma dissection using focused ultrasound under MRI control. The first successful experience in Russia]. [在核磁共振成像控制下使用聚焦超声进行下丘脑火腿肠瘤切除术。俄罗斯首次成功经验]。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.17116/neiro20248801179
R M Galimova, S N Illarioshkin, Sh M Safin, I V Buzaev, D I Nabiullina, D K Krekotin, S R Nurmukhametova, Yu A Sidorova, G N Akhmadeeva, F F Kashapov, T Z Yakupov, D R Teregulova

Treatment of motor disorders by MRI-guided focused ultrasound is an alternative to neuro- and radiosurgery such as stereotactic radiofrequency ablation and thalamotomy with a gamma knife. However, safety, efficacy and feasibility of this technology for intracranial neoplasms are still unclear. The authors report successful hypothalamic hamartoma dissection by MRI-guided focused ultrasound in a 32-year-old woman with drug-resistant gelastic epilepsy and violent laughter and crying attacks. Magnetic resonance imaging revealed type II hypothalamic hamartoma. The last one was detached from surrounding brain tissue by MRI-guided focused ultrasound without side effects. Symptoms regressed immediately after surgery. No laughter and crying attacks were observed throughout 6-month follow-up.

通过磁共振成像引导的聚焦超声治疗运动障碍是立体定向射频消融术和伽玛刀丘脑切开术等神经外科和放射外科手术的替代方法。然而,这项技术对颅内肿瘤的安全性、有效性和可行性仍不明确。作者报告了通过磁共振成像引导下的聚焦超声成功切除下丘脑仓瘤的病例,患者是一名32岁的女性,患有耐药性凝胶样癫痫和暴笑暴哭发作。磁共振成像显示她患有 II 型下丘脑火腿肠瘤。通过核磁共振引导下的聚焦超声,最后一个瘤体与周围脑组织分离,无副作用。术后症状立即缓解。在 6 个月的随访中,没有观察到笑和哭发作。
{"title":"[Hypothalamic hamartoma dissection using focused ultrasound under MRI control. The first successful experience in Russia].","authors":"R M Galimova, S N Illarioshkin, Sh M Safin, I V Buzaev, D I Nabiullina, D K Krekotin, S R Nurmukhametova, Yu A Sidorova, G N Akhmadeeva, F F Kashapov, T Z Yakupov, D R Teregulova","doi":"10.17116/neiro20248801179","DOIUrl":"10.17116/neiro20248801179","url":null,"abstract":"<p><p>Treatment of motor disorders by MRI-guided focused ultrasound is an alternative to neuro- and radiosurgery such as stereotactic radiofrequency ablation and thalamotomy with a gamma knife. However, safety, efficacy and feasibility of this technology for intracranial neoplasms are still unclear. The authors report successful hypothalamic hamartoma dissection by MRI-guided focused ultrasound in a 32-year-old woman with drug-resistant gelastic epilepsy and violent laughter and crying attacks. Magnetic resonance imaging revealed type II hypothalamic hamartoma. The last one was detached from surrounding brain tissue by MRI-guided focused ultrasound without side effects. Symptoms regressed immediately after surgery. No laughter and crying attacks were observed throughout 6-month follow-up.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139708070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Information support for the bioresource collection: a biological information system «NeuroOnc»]. [生物资源收集的信息支持:生物信息系统 "NeuroOnc"]。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.17116/neiro20248803165
M A Shifrin, T V Tsukanova, G V Pavlova, G V Danilov, I N Pronin

The manuscript is devoted to development of information support system for a bioresource collection - biological information system «NeuroOnc». Architecture and main functions of system are presented. This system was formed in the project «Development of bioresource collection of tumors of the human nervous system with molecular genetic certification for personalized treatment of patients with neuro-oncological diseases». The purpose of this project was not only formation of bioresource collection, but also development of various molecular genetic methods for analysis of biospecimens in context of clinical researches. Biological information systems created to support the work of bioresource collections in hospitals should become a natural part of information infrastructure. Information support of bioresource collections cannot imply only «warehouse» functions. This system should have tools to support various scientific and clinical researches. Biological information systems can sometimes expand medical information systems but remain sufficiently autonomous. It is advisable to develop biological information systems in large specialized companies that can support their products for many years.

该手稿致力于开发生物资源收集的信息支持系统--生物信息系统 "NeuroOnc"。文中介绍了该系统的结构和主要功能。该系统是在 "为神经肿瘤疾病患者的个性化治疗开发具有分子遗传学认证的人类神经系统肿瘤生物资源库 "项目中建立的。该项目的目的不仅是建立生物资源库,还包括开发各种分子遗传方法,以便在临床研究中对生物样本进行分析。为支持医院生物资源收集工作而建立的生物信息系统应成为信息基础设施的自然组成部 分。对生物资源收集工作的信息支持不能仅仅意味着 "仓库 "功能。该系统应具备支持各种科学和临床研究的工具。生物信息系统有时可以扩展医疗信息系统,但仍应保持足够的独立性。建议在大型专业公司开发生物信息系统,以支持其产品多年的发展。
{"title":"[Information support for the bioresource collection: a biological information system «NeuroOnc»].","authors":"M A Shifrin, T V Tsukanova, G V Pavlova, G V Danilov, I N Pronin","doi":"10.17116/neiro20248803165","DOIUrl":"https://doi.org/10.17116/neiro20248803165","url":null,"abstract":"<p><p>The manuscript is devoted to development of information support system for a bioresource collection - biological information system «NeuroOnc». Architecture and main functions of system are presented. This system was formed in the project «Development of bioresource collection of tumors of the human nervous system with molecular genetic certification for personalized treatment of patients with neuro-oncological diseases». The purpose of this project was not only formation of bioresource collection, but also development of various molecular genetic methods for analysis of biospecimens in context of clinical researches. Biological information systems created to support the work of bioresource collections in hospitals should become a natural part of information infrastructure. Information support of bioresource collections cannot imply only «warehouse» functions. This system should have tools to support various scientific and clinical researches. Biological information systems can sometimes expand medical information systems but remain sufficiently autonomous. It is advisable to develop biological information systems in large specialized companies that can support their products for many years.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141331880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Aggressive pituitary tumors and carcinomas: modern classification, advances and prospects in treatment]. [侵袭性垂体瘤和癌:现代分类、治疗进展和前景]。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.17116/neiro202488031103
L I Astafyeva, P L Kalinin, G L Kobyakov, Yu Yu Trunin, M V Ryzhova

Despite slow growth of most pituitary tumors and high rates of total resection and/or effective therapy, pituitary neoplasms are characterized by aggressive behavior with high growth rate, frequent relapses and resistance to standard treatments in 10% of cases. In modern WHO classifications of tumors of the central nervous system, endocrine and neuroendocrine tumors, the authors propose the definition «pituitary neuroendocrine tumor» instead of previous «pituitary adenoma» and «metastasizing pituitary neuroendocrine tumor» instead of «pituitary carcinoma». Currently, there are no effective prognostic markers of aggressive tumors. This complicates early diagnosis. It is proposed to apply a five-stage prognostic classification based on proliferation rate (including mitotic count, Ki-67 index and p53 immunoexpression) and morphometric markers of invasiveness for all resected pituitary neoplasms. This approach would be valuable for earlier detection of aggressive tumors and pituitary carcinomas. Compression of visual pathways, third ventricle and brain stem due to rapid growth of aggressive tumors usually requires redo surgeries with subsequent radiotherapy. Hormonally active tumors require therapy with somatostatin analogues and dopamine agonists in maximum possible doses. Chemotherapy with temozolomide as first-line option is recommended if standard treatment is ineffective. Alternative treatment includes peptide receptor radionuclide therapy (PRRT), molecular targeted therapy (bevacizumab, tyrosine kinase inhibitors, everolimus and cyclin-dependent kinase inhibitors) and immunotherapy (checkpoint inhibitors). Considering the need for combined treatment, these cases should always be discussed by a multidisciplinary team (neurosurgeon, endocrinologist, radiotherapist, oncologist, pathologist) with necessary qualifications and experience in treating these patients. Treatment of aggressive tumors and pituitary carcinomas is becoming an active and rapidly developing direction in neurosurgery, endocrinology and oncology.

尽管大多数垂体瘤生长缓慢,全切除率和/或有效治疗率较高,但垂体瘤的特点是侵袭性强、生长率高、复发频繁,10%的病例对标准治疗有抵抗力。在世界卫生组织对中枢神经系统肿瘤、内分泌肿瘤和神经内分泌肿瘤的现代分类中,作者提出了 "垂体神经内分泌肿瘤 "的定义,而不是以前的 "垂体腺瘤",也提出了 "转移性垂体神经内分泌肿瘤 "的定义,而不是 "垂体癌"。目前,侵袭性肿瘤还没有有效的预后标志物。这使得早期诊断变得复杂。建议对所有切除的垂体肿瘤采用基于增殖率(包括有丝分裂计数、Ki-67 指数和 p53 免疫表达)和侵袭性形态计量标记的五阶段预后分类。这种方法对早期发现侵袭性肿瘤和垂体癌很有价值。侵袭性肿瘤快速生长导致视觉通路、第三脑室和脑干受压,通常需要重新进行手术,并随后进行放射治疗。激素活跃的肿瘤需要使用最大剂量的体生长抑素类似物和多巴胺激动剂进行治疗。如果标准治疗无效,建议将替莫唑胺化疗作为一线选择。替代治疗包括肽受体放射性核素治疗(PRRT)、分子靶向治疗(贝伐珠单抗、酪氨酸激酶抑制剂、依维莫司和细胞周期蛋白依赖性激酶抑制剂)和免疫治疗(检查点抑制剂)。考虑到联合治疗的必要性,这些病例应始终由具有治疗此类患者的必要资质和经验的多学科团队(神经外科医生、内分泌科医生、放射治疗医生、肿瘤科医生、病理科医生)进行讨论。侵袭性肿瘤和垂体癌的治疗正成为神经外科、内分泌学和肿瘤学中一个活跃而快速发展的方向。
{"title":"[Aggressive pituitary tumors and carcinomas: modern classification, advances and prospects in treatment].","authors":"L I Astafyeva, P L Kalinin, G L Kobyakov, Yu Yu Trunin, M V Ryzhova","doi":"10.17116/neiro202488031103","DOIUrl":"https://doi.org/10.17116/neiro202488031103","url":null,"abstract":"<p><p>Despite slow growth of most pituitary tumors and high rates of total resection and/or effective therapy, pituitary neoplasms are characterized by aggressive behavior with high growth rate, frequent relapses and resistance to standard treatments in 10% of cases. In modern WHO classifications of tumors of the central nervous system, endocrine and neuroendocrine tumors, the authors propose the definition «pituitary neuroendocrine tumor» instead of previous «pituitary adenoma» and «metastasizing pituitary neuroendocrine tumor» instead of «pituitary carcinoma». Currently, there are no effective prognostic markers of aggressive tumors. This complicates early diagnosis. It is proposed to apply a five-stage prognostic classification based on proliferation rate (including mitotic count, Ki-67 index and p53 immunoexpression) and morphometric markers of invasiveness for all resected pituitary neoplasms. This approach would be valuable for earlier detection of aggressive tumors and pituitary carcinomas. Compression of visual pathways, third ventricle and brain stem due to rapid growth of aggressive tumors usually requires redo surgeries with subsequent radiotherapy. Hormonally active tumors require therapy with somatostatin analogues and dopamine agonists in maximum possible doses. Chemotherapy with temozolomide as first-line option is recommended if standard treatment is ineffective. Alternative treatment includes peptide receptor radionuclide therapy (PRRT), molecular targeted therapy (bevacizumab, tyrosine kinase inhibitors, everolimus and cyclin-dependent kinase inhibitors) and immunotherapy (checkpoint inhibitors). Considering the need for combined treatment, these cases should always be discussed by a multidisciplinary team (neurosurgeon, endocrinologist, radiotherapist, oncologist, pathologist) with necessary qualifications and experience in treating these patients. Treatment of aggressive tumors and pituitary carcinomas is becoming an active and rapidly developing direction in neurosurgery, endocrinology and oncology.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141331876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Five-year follow-up after neurosurgery complicated by facial neuropathy]. [神经外科手术后并发面部神经病变的五年随访]。
Q4 Medicine Pub Date : 2024-01-01 DOI: 10.17116/neiro20248804150
M A Akulov, O R Orlova, V N Shimansky, S V Tanyashin, V K Poshataev, V O Zakharov

Background: Botulinum toxin A (BTA) injections are effective for facial neuropathy. However, there is insufficient number of studies devoted to long-term management of these patients.

Objective: To evaluate the effectiveness and safety of BTA therapy in patients with facial neuropathy after neurosurgical interventions.

Material and methods: The study included 86 patients with facial neuropathy after surgical treatment of posterior cranial fossa and cerebellopontine angle tumors. All ones were divided into 2 groups: group I (main) - 57 patients with BTA prescribed early after facial nerve injury, group II (control) - 29 people undergoing exercise therapy, as well as special exercises and acupressure of painful muscle cords. The Sunnybrook Facial Grading Scale (SFGS) was used to assess facial symmetry and synkinesis, the Facial Disability Index (FDI scale) - to assess the quality of life. Overall duration of the study was 5 years (control points: 6 months, 1, 2, 3 and 5 years).

Results: The SFGS scores after 1, 2, 3 and 5 years were significantly better in the main group (resting symmetry p<0.01, voluntary movement symmetry p<0.01, synkinesis p<0.01, general condition of facial muscles p<0.01). Scores of physical and social functioning were significantly higher in the main group after 1 (p<0.01), 2 (p<0.01), 3 (p<0.01) and 5 years (p<0.01) after surgery. There was no need to change BTA dosage over 5 years. Thus, this form of BTA may be the most effective for synkinesis of facial muscles.

Conclusion: Correction of synkinesis caused by facial neuropathy requires long-term follow-up and long-term treatment. BTA is effective and may be recommended for long-term treatment of these patients.

背景:肉毒杆菌毒素 A(BTA)注射对面部神经病变有效。然而,专门针对这些患者长期治疗的研究数量不足:评估神经外科干预后面部神经病变患者接受 BTA 治疗的有效性和安全性:研究纳入了86例经手术治疗后颅窝和小脑角肿瘤的面部神经病变患者。所有患者分为两组:第一组(主要组)--57 名患者在面神经损伤后早期接受 BTA 治疗;第二组(对照组)--29 名患者接受运动疗法以及特殊运动和疼痛肌群穴位按摩。桑尼布鲁克面部分级量表(SFGS)用于评估面部对称性和同步性,面部残疾指数(FDI量表)用于评估生活质量。研究的总体持续时间为 5 年(对照点:6 个月、1 年、2 年、3 年和 5 年):结果:1、2、3 和 5 年后,主要研究组的 SFGS 评分明显提高(静息对称性评分):面神经病变引起的同步运动障碍的矫正需要长期的随访和长期的治疗。BTA 疗效显著,可推荐用于此类患者的长期治疗。
{"title":"[Five-year follow-up after neurosurgery complicated by facial neuropathy].","authors":"M A Akulov, O R Orlova, V N Shimansky, S V Tanyashin, V K Poshataev, V O Zakharov","doi":"10.17116/neiro20248804150","DOIUrl":"10.17116/neiro20248804150","url":null,"abstract":"<p><strong>Background: </strong>Botulinum toxin A (BTA) injections are effective for facial neuropathy. However, there is insufficient number of studies devoted to long-term management of these patients.</p><p><strong>Objective: </strong>To evaluate the effectiveness and safety of BTA therapy in patients with facial neuropathy after neurosurgical interventions.</p><p><strong>Material and methods: </strong>The study included 86 patients with facial neuropathy after surgical treatment of posterior cranial fossa and cerebellopontine angle tumors. All ones were divided into 2 groups: group I (main) - 57 patients with BTA prescribed early after facial nerve injury, group II (control) - 29 people undergoing exercise therapy, as well as special exercises and acupressure of painful muscle cords. The Sunnybrook Facial Grading Scale (SFGS) was used to assess facial symmetry and synkinesis, the Facial Disability Index (FDI scale) - to assess the quality of life. Overall duration of the study was 5 years (control points: 6 months, 1, 2, 3 and 5 years).</p><p><strong>Results: </strong>The SFGS scores after 1, 2, 3 and 5 years were significantly better in the main group (resting symmetry <i>p</i><0.01, voluntary movement symmetry <i>p</i><0.01, synkinesis <i>p</i><0.01, general condition of facial muscles <i>p</i><0.01). Scores of physical and social functioning were significantly higher in the main group after 1 (<i>p</i><0.01), 2 (<i>p</i><0.01), 3 (<i>p</i><0.01) and 5 years (<i>p</i><0.01) after surgery. There was no need to change BTA dosage over 5 years. Thus, this form of BTA may be the most effective for synkinesis of facial muscles.</p><p><strong>Conclusion: </strong>Correction of synkinesis caused by facial neuropathy requires long-term follow-up and long-term treatment. BTA is effective and may be recommended for long-term treatment of these patients.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142018878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Autologous fibrin glue for endoscopic skull base repair in patients with cerebrospinal fluid leakage]. 自体纤维蛋白胶在脑脊液漏患者颅底修复中的应用
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/neiro20238701149
E V Shelesko, V A Doronina, O I Sharipov, O K Kvan, N A Chernikova, Yu V Strunina, D N Zinkevich

The main stages of endoscopic skull base repair in patients with cerebrospinal fluid (CSF) leakage are identification of bone boundaries of the fistula and its closure by auto- and allografts. Fibrin glue can be used to fix plastic materials and additionally seal skull base defect.

Objective: To analyze efficacy and safety of Vivostat autologous fibrin glue for endoscopic skull base repair in patients with nasal CSF leakage and to compare postoperative outcomes after defect closure by Vivostat fibrin glue and allogeneic fibrin glue.

Material and methods: A retro- and prospective analysis included 56 patients with nasal CSF leakage who were treated at the Burdenko Neurosurgery Center between January 2021 and June 2022. Patients were divided into 2 groups: Vivostat fibrin glue (n=27, 48.2%) and allogeneic fibrin glue (n=29, 51.8%). Demographic and clinical perioperative data were analyzed.

Results: No early postoperative recurrence of CSF leakage was registered in both groups, whereas meningitis occurred in 2 cases in each group. Recurrent CSF leakage in delayed postoperative period occurred in 1 patient (3.4%) of the control group (p>0.05). Incidence of perioperative complications, subfebrile temperature in early postoperative period, surgery time and hospital-stay were similar.

Conclusion: Vivostat autologous fibrin glue is a safe and effective method for fixing the grafts in endoscopic skull base repair. The advantages of this approach are easy application, elimination of the risk of allergic, immunological and infectious complications, as well as acceleration of tissue regeneration.

脑脊液(CSF)漏患者的内镜颅底修复的主要阶段是确定瘘的骨边界,并通过自体和同种异体移植物关闭瘘。纤维蛋白胶可用于塑料材料的固定,也可用于颅底缺损的封闭。目的:分析Vivostat自体纤维蛋白胶用于鼻脑脊液漏鼻内镜颅底修复的疗效和安全性,并比较Vivostat纤维蛋白胶与异体纤维蛋白胶缝合缺损的术后效果。材料和方法:回顾性和前瞻性分析包括56例鼻脑脊液漏患者,这些患者于2021年1月至2022年6月在Burdenko神经外科中心接受治疗。患者分为两组:Vivostat纤维蛋白胶(n=27, 48.2%)和同种异体纤维蛋白胶(n=29, 51.8%)。分析人口学和临床围手术期资料。结果:两组术后早期均无脑脊液漏复发,两组均有2例脑膜炎发生。对照组术后迟发期复发脑脊液漏1例(3.4%),差异有统计学意义(p>0.05)。围手术期并发症发生率、术后早期亚热体温、手术时间、住院时间相似。结论:Vivostat自体纤维蛋白胶是内镜下颅底修复中固定移植物安全有效的方法。这种方法的优点是易于应用,消除过敏、免疫和感染并发症的风险,以及加速组织再生。
{"title":"[Autologous fibrin glue for endoscopic skull base repair in patients with cerebrospinal fluid leakage].","authors":"E V Shelesko, V A Doronina, O I Sharipov, O K Kvan, N A Chernikova, Yu V Strunina, D N Zinkevich","doi":"10.17116/neiro20238701149","DOIUrl":"10.17116/neiro20238701149","url":null,"abstract":"<p><p>The main stages of endoscopic skull base repair in patients with cerebrospinal fluid (CSF) leakage are identification of bone boundaries of the fistula and its closure by auto- and allografts. Fibrin glue can be used to fix plastic materials and additionally seal skull base defect.</p><p><strong>Objective: </strong>To analyze efficacy and safety of Vivostat autologous fibrin glue for endoscopic skull base repair in patients with nasal CSF leakage and to compare postoperative outcomes after defect closure by Vivostat fibrin glue and allogeneic fibrin glue.</p><p><strong>Material and methods: </strong>A retro- and prospective analysis included 56 patients with nasal CSF leakage who were treated at the Burdenko Neurosurgery Center between January 2021 and June 2022. Patients were divided into 2 groups: Vivostat fibrin glue (<i>n</i>=27, 48.2%) and allogeneic fibrin glue (<i>n</i>=29, 51.8%). Demographic and clinical perioperative data were analyzed.</p><p><strong>Results: </strong>No early postoperative recurrence of CSF leakage was registered in both groups, whereas meningitis occurred in 2 cases in each group. Recurrent CSF leakage in delayed postoperative period occurred in 1 patient (3.4%) of the control group (<i>p</i>>0.05). Incidence of perioperative complications, subfebrile temperature in early postoperative period, surgery time and hospital-stay were similar.</p><p><strong>Conclusion: </strong>Vivostat autologous fibrin glue is a safe and effective method for fixing the grafts in endoscopic skull base repair. The advantages of this approach are easy application, elimination of the risk of allergic, immunological and infectious complications, as well as acceleration of tissue regeneration.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9233556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
[Repeated cervical laminoplasty for progressive ossification of posterior longitudinal ligament: a case report]. 反复颈椎椎板成形术治疗后纵韧带进行性骨化1例。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/neiro20238701190
Sh Sh Magomedov, P G Mytyga

Posterior longitudinal ligament ossification is a progressive disease resulting in severe multilevel spinal stenosis with myelopathy. Decompression via anterior or posterior approach is the main treatment option. Decompressive laminoplasty is currently considered the most effective and safest method. This procedure provides favorable outcomes with low trauma and short surgery time. Redo surgeries are rare and most often performed within 2 years after primary laminoplasty. The most common causes are progressive spinal stenosis following posterior longitudinal ligament ossification, insufficient primary decompression and progressive cervical spine kyphosis. Considering few data on redo laminoplasty, we present a patient with progressive ossification of posterior longitudinal ligament who underwent redo surgery at the same level in 10 years after primary laminoplasty.

后纵韧带骨化是一种进行性疾病,导致严重的多节段椎管狭窄伴脊髓病。经前路或后路减压是主要的治疗选择。椎板减压成形术目前被认为是最有效和最安全的方法。该方法创伤小,手术时间短,效果好。重做手术是罕见的,通常在初级椎板成形术后2年内进行。最常见的原因是后纵韧带骨化后进行性椎管狭窄,初级减压不足和进行性颈椎后凸。考虑到关于重做椎板成形术的数据很少,我们报告了一例后侧纵韧带进行性骨化的患者,他在初次椎板成形术后的10年内接受了相同水平的重做手术。
{"title":"[Repeated cervical laminoplasty for progressive ossification of posterior longitudinal ligament: a case report].","authors":"Sh Sh Magomedov, P G Mytyga","doi":"10.17116/neiro20238701190","DOIUrl":"10.17116/neiro20238701190","url":null,"abstract":"<p><p>Posterior longitudinal ligament ossification is a progressive disease resulting in severe multilevel spinal stenosis with myelopathy. Decompression via anterior or posterior approach is the main treatment option. Decompressive laminoplasty is currently considered the most effective and safest method. This procedure provides favorable outcomes with low trauma and short surgery time. Redo surgeries are rare and most often performed within 2 years after primary laminoplasty. The most common causes are progressive spinal stenosis following posterior longitudinal ligament ossification, insufficient primary decompression and progressive cervical spine kyphosis. Considering few data on redo laminoplasty, we present a patient with progressive ossification of posterior longitudinal ligament who underwent redo surgery at the same level in 10 years after primary laminoplasty.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10708060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Etiopathogenetic substantiation of surgical treatment of neurogenic pain syndromes]. 神经源性疼痛综合征的外科治疗的病因学依据。
Q4 Medicine Pub Date : 2023-01-01 DOI: 10.17116/neiro20238701155
O N Dreval, K V Lyubimaya, A V Kuznetsov, O V Mukhina, I I Tsuladze, G Yu Grigoryan, G N Chapandze, D A Chagava, A G Fedyakov

The purpose of the study was to improve classification of neurogenic (neuropathic) pain syndromes. This will make it possible to define the indications for appropriate analgesic surgery for each type of drug-resistant neurogenic pain syndrome. Incorrect management of neurogenic pain syndromes is usually associated with underestimation of pathogenetic prerequisites for its occurrence. Differentiation of compression, deafferentation and mixed neurogenic pain syndromes makes it possible to determine appropriate surgery and avoid tactical errors. Moreover, this approach allows you to save patients from unreasonable long-standing suffering. Patients with chronic pain syndromes often become disabled, sometimes in the prime of life, and isolated from society and family. Therefore, treatment of chronic pain is currently an urgent problem.

该研究的目的是改进神经源性(神经性)疼痛综合征的分类。这将使我们有可能为每种类型的耐药神经源性疼痛综合征确定合适的镇痛手术适应症。神经源性疼痛综合征的不正确处理通常与低估其发生的病理先决条件有关。区分压迫、神经传导障碍和混合神经性疼痛综合征,可以确定适当的手术并避免战术错误。此外,这种方法可以使患者免于不合理的长期痛苦。患有慢性疼痛综合征的患者往往会残疾,有时正值壮年,并与社会和家庭隔绝。因此,慢性疼痛的治疗是目前迫切需要解决的问题。
{"title":"[Etiopathogenetic substantiation of surgical treatment of neurogenic pain syndromes].","authors":"O N Dreval, K V Lyubimaya, A V Kuznetsov, O V Mukhina, I I Tsuladze, G Yu Grigoryan, G N Chapandze, D A Chagava, A G Fedyakov","doi":"10.17116/neiro20238701155","DOIUrl":"10.17116/neiro20238701155","url":null,"abstract":"<p><p>The purpose of the study was to improve classification of neurogenic (neuropathic) pain syndromes. This will make it possible to define the indications for appropriate analgesic surgery for each type of drug-resistant neurogenic pain syndrome. Incorrect management of neurogenic pain syndromes is usually associated with underestimation of pathogenetic prerequisites for its occurrence. Differentiation of compression, deafferentation and mixed neurogenic pain syndromes makes it possible to determine appropriate surgery and avoid tactical errors. Moreover, this approach allows you to save patients from unreasonable long-standing suffering. Patients with chronic pain syndromes often become disabled, sometimes in the prime of life, and isolated from society and family. Therefore, treatment of chronic pain is currently an urgent problem.</p>","PeriodicalId":24032,"journal":{"name":"Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10708063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Zhurnal voprosy neirokhirurgii imeni N. N. Burdenko
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1